In NSCLC patients receiving PD-1 blockade, SIRPG is highly expressed in responders and patients with high levels of SIRPG expression were associated with better clinical outcomes, which was validated in the melanoma cohort. Here, SIRPG is linked to non-small cell lung carcinoma.